Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Operates in Healthcare Services. Per the activity note to the FY2024 annual report, the company operates as a clinical research organization conducting trials and studies globally.
Subsidiary of Shezghuduli Pasukhismgeblobis Sazogadoeba Pareksel International Holding Bi.vi. (100.0%)
| Ratio | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Margins | ||||||
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| EBITDA Margin | 25.2% | 4.8% | 10.5% | 8.3% | 5.3% | 7.5% |
| EBITDAR | 1,331 | 581 | 995 | 967 | 879 | 1,074 |
| EBITDAR Margin | 34.5% | 18.0% | 19.1% | 14.7% | 9.7% | 10.4% |
| EBIT Margin | 22.1% | 0.6% | 7.9% | 6.3% | 4.2% | 6.1% |
| Net Profit Margin | 22.0% | 6.7% | 5.6% | 0.7% | 7.7% | 6.2% |
| Operating Expense % of Sales | 74.8% | 95.2% | 89.5% | 91.7% | 94.7% | 92.5% |
| Returns | ||||||
| Return on Assets (ROA) | 40.4% | 9.1% | 8.5% | 0.5% | 17.0% | 12.9% |
| Return on Equity (ROE) | 48.3% | 10.9% | 13.0% | 2.0% | 23.2% | 17.5% |
| ROIC [EBIT / Invested Capital] | 165.6% | 2.2% | N/A | 93.9% | 80.6% | 52.5% |
| Leverage & debt balances | ||||||
| Debt-to-Assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Debt-to-Equity | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| Debt-to-EBITDA | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| Equity-to-Assets | 83.6% | 83.2% | 65.9% | 24.6% | 73.3% | 73.6% |
| Net Debt | -1,239 | -1,063 | -2,935 | -1,865 | -2,537 | -2,446 |
| Cash & Equivalents | 1,239 | 1,063 | 2,935 | 1,865 | 2,537 | 2,446 |
| Total Debt | N/A | N/A | N/A | N/A | N/A | N/A |
| Liquidity & working capital | ||||||
| Current Ratio | 5.51x | 5.80x | 2.75x | 1.28x | 3.42x | 3.48x |
| Quick Ratio | 5.51x | 5.80x | 2.75x | 1.28x | 3.42x | 3.48x |
| Cash Ratio | 3.94x | 2.90x | 2.57x | 0.26x | 2.31x | 1.87x |
| Total Current Assets | 1,734 | 2,126 | 3,140 | 9,086 | 3,751 | 4,549 |
| Total Current Liabilities | 315 | 367 | 1,141 | 7,091 | 1,096 | 1,305 |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A |
| Trade Receivables | 197 | 657 | 106 | 7,122 | 1,113 | 2,022 |
| Trade Payables | 115 | 181 | 735 | 6,386 | 401 | 422 |
| Net Working Capital | 1,420 | 1,759 | 1,999 | 1,995 | 2,655 | 3,244 |
| Net Working Capital % of Revenue | 36.8% | 54.6% | 38.4% | 30.4% | 29.3% | 31.5% |
| Trade Working Capital | 82 | 476 | -628 | 736 | 712 | 1,600 |
| Trade Working Capital % of Revenue | 2.1% | 14.8% | -12.1% | 11.2% | 7.8% | 15.5% |
| Change in Trade Working Capital | N/A | 394 | -1,104 | 1,364 | -24 | 888 |
| Turnover & efficiency | ||||||
| Inventory Turnover | N/A | N/A | N/A | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | N/A | N/A | N/A | N/A | N/A | N/A |
| Receivables Turnover | 19.58x | 4.90x | 49.03x | 0.92x | 8.16x | 5.09x |
| Days Sales Outstanding (DSO) | 18.6 | 74.5 | 7.4 | 395.9 | 44.8 | 71.7 |
| Payables Turnover | N/A | N/A | N/A | N/A | N/A | N/A |
| Days Payable Outstanding (DPO) | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Conversion Cycle | 18.6 days | 74.5 days | 7.4 days | 395.9 days | 44.8 days | 71.7 days |
| Asset Turnover | 1.84x | 1.36x | 1.52x | 0.70x | 2.21x | 2.08x |
| Cash flow & dividends | ||||||
| Operating Cash Flow | 1,059 | -773 | 2,275 | -546 | N/A | N/A |
| Free Cash Flow (OCF − Capex proxy) | 1,012 | -773 | 2,061 | -729 | N/A | N/A |
| Cash Conversion (OCF / EBITDA) | 108.9% | -497.3% | 414.6% | -99.7% | N/A | N/A |
| Dividends Declared | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in GEL, thousands. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →